JP2024532619A5 - - Google Patents

Info

Publication number
JP2024532619A5
JP2024532619A5 JP2024537306A JP2024537306A JP2024532619A5 JP 2024532619 A5 JP2024532619 A5 JP 2024532619A5 JP 2024537306 A JP2024537306 A JP 2024537306A JP 2024537306 A JP2024537306 A JP 2024537306A JP 2024532619 A5 JP2024532619 A5 JP 2024532619A5
Authority
JP
Japan
Prior art keywords
seq
amino acid
receptor antibody
acid sequence
pharmaceutical composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024537306A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024532619A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2022/075545 external-priority patent/WO2023028606A1/en
Publication of JP2024532619A publication Critical patent/JP2024532619A/ja
Publication of JP2024532619A5 publication Critical patent/JP2024532619A5/ja
Pending legal-status Critical Current

Links

JP2024537306A 2021-08-27 2022-08-26 併用療法 Pending JP2024532619A (ja)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US202163238068P 2021-08-27 2021-08-27
US63/238,068 2021-08-27
US202263301012P 2022-01-19 2022-01-19
US63/301,012 2022-01-19
US202263333351P 2022-04-21 2022-04-21
US63/333,351 2022-04-21
PCT/US2022/075545 WO2023028606A1 (en) 2021-08-27 2022-08-26 Combination therapies

Publications (2)

Publication Number Publication Date
JP2024532619A JP2024532619A (ja) 2024-09-05
JP2024532619A5 true JP2024532619A5 (cg-RX-API-DMAC7.html) 2025-09-01

Family

ID=83897998

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024537306A Pending JP2024532619A (ja) 2021-08-27 2022-08-26 併用療法

Country Status (11)

Country Link
US (1) US20240325530A1 (cg-RX-API-DMAC7.html)
EP (1) EP4392137A1 (cg-RX-API-DMAC7.html)
JP (1) JP2024532619A (cg-RX-API-DMAC7.html)
KR (1) KR20240099142A (cg-RX-API-DMAC7.html)
CN (1) CN118488853A (cg-RX-API-DMAC7.html)
AU (1) AU2022332306A1 (cg-RX-API-DMAC7.html)
CA (1) CA3229355A1 (cg-RX-API-DMAC7.html)
IL (1) IL310919A (cg-RX-API-DMAC7.html)
MX (1) MX2024002467A (cg-RX-API-DMAC7.html)
TW (1) TW202323296A (cg-RX-API-DMAC7.html)
WO (1) WO2023028606A1 (cg-RX-API-DMAC7.html)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4121078A4 (en) 2020-03-20 2024-08-14 Keros Therapeutics, Inc. ACTIVIN RECEPTOR TYPE II CHIMERAS AND METHODS OF USE THEREOF
EP4121088A4 (en) 2020-03-20 2024-07-03 Keros Therapeutics, Inc. Methods of using activin receptor type iib variants
SI4408840T1 (sl) 2021-09-27 2025-12-31 Terns Pharmaceuticals, Inc. Benzimidazolne karboksilne kisline kot agonisti GLP-1R
US12024507B2 (en) 2021-10-25 2024-07-02 Terns Pharmaceuticals, Inc. Compounds as GLP-1R agonists
EP4466288A4 (en) * 2022-01-19 2026-02-25 Versanis Bio Inc ACTRII ANTIBODY-BASED TREATMENTS
AU2023224854A1 (en) 2022-02-23 2024-10-03 Terns Pharmaceuticals, Inc. Compounds as glp-1r agonists
EP4577301A1 (en) 2022-08-26 2025-07-02 Versanis Bio, Inc. Actrii antibody fixed unit dose treatments
PE20252787A1 (es) 2023-04-07 2025-12-22 Terns Pharmaceuticals Inc Combinacion que comprende un agonista de thr-beta y un agonista de glp-1r para su uso en el tratamiento de un trastorno hepatico o una enfermedad cardiometabolica
IL326224A (en) 2023-07-31 2026-03-01 Sixpeaks Bio Ag Antibody conjugates and fusion proteins
WO2025106773A1 (en) * 2023-11-17 2025-05-22 Apnimed, Inc. (Delaware) Methods and compositions for treating sleep apnea with a combination of a glp-1 agonist and a second active agent
IL330385A (en) * 2023-12-29 2026-08-01 Jiangsu Hengrui Pharmaceuticals Co Ltd Antibody-polypeptide conjugate and its pharmaceutical use
WO2025147483A1 (en) * 2024-01-02 2025-07-10 Keros Therapeutics, Inc. Methods of using activin receptor type ii chimeras
WO2025183966A1 (en) 2024-02-28 2025-09-04 Versanis Bio, Inc. Actrii antibodies with extended half life
WO2025217521A1 (en) * 2024-04-12 2025-10-16 Jnana Therapeutics Inc. Treating chronic kidney disease with a combination of a slc6a19 inhibitor and a glp-1 agonist
WO2025247309A1 (zh) * 2024-05-31 2025-12-04 上海齐鲁制药研究中心有限公司 融合蛋白分子及其应用
WO2026128614A1 (en) * 2024-12-10 2026-06-18 Supercede Therapeutics, Inc. Activin receptor type ii inhibitors for preventing or treating obesity and related disorders
EP4785960A1 (en) 2025-01-31 2026-08-05 SixPeaks Bio AG Glp-1 antibody conjugates

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2655877T3 (es) 2009-04-27 2018-02-22 Novartis Ag Composiciones y métodos para aumentar el crecimiento muscular
JOP20190152A1 (ar) 2016-12-21 2019-06-20 Novartis Ag مضادات الميوستاتين، الآكتيفين أو مستقبلات الآكتيفين للاستخدام في علاج السمنة والحالات ذات الصلة
WO2018129395A1 (en) * 2017-01-06 2018-07-12 Scholar Rock, Inc. Methods for treating metabolic diseases by inhibiting myostatin activation

Similar Documents

Publication Publication Date Title
JP7094327B2 (ja) 新規なオキシントモジュリン誘導体及びそれを含む肥満治療用組成物
US20240325530A1 (en) Combination therapies
EP3398961B1 (en) Triple activator activating glucagon, glp-1 and gip receptor
US11135271B2 (en) Glucagon derivatives with improved stability
JP2023510609A (ja) Glp-1および/またはglp-1類似体、ならびにインスリンおよび/またはインスリン類似体を含む併用療法
EP4577301A1 (en) Actrii antibody fixed unit dose treatments
CN121152634A (zh) 用于治疗恶心和呕吐的方法和用途
WO2024027553A1 (zh) 一种双功能融合蛋白及其用途
CN115212293A (zh) 一种融合蛋白的制药用途
WO2025183966A1 (en) Actrii antibodies with extended half life
JP2023518645A (ja) Glp-1の投薬レジメン
KR20250095833A (ko) 에페글레나타이드를 유효성분으로 포함하는 약학 조성물 및 이의 투여 요법
HK40094446A (en) Glp-1 dosing regimen
CA2972748C (en) Glucagon derivatives with improved stability
HK40010066A (en) Glucagon derivative
WO2025259957A1 (en) Compositions and methods for improving insulin sensitivity
KR20180027924A (ko) 글루카곤 유사 펩타이드-1(glp-1), glp-1 유래 펩타이드, 또는 glp-1 분해 억제제를 포함하는 근감소증 또는 근위축증 치료용 약학 조성물
HK40083623A (en) Dosing regimen of glp-1
HK40010066B (en) Glucagon derivative
CA3162463A1 (en) Combination therapy using glucagon and glp-1 co-agonists for the treatment of obesity
TW202140061A (zh) 用於治療2型糖尿病中的慢性腎病和糖尿病性腎病的升糖素及glp-1協同促效劑
BR112017014205B1 (pt) Derivados de glucagon e seu uso, e uso de uma composição farmacêutica